- Home
- TDC vs SRPT Comparison
TDC vs SRPT Comparison
Compare TDC & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TDC | SRPT |
|---|---|---|
| Founded | 1979 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 2.3B |
| IPO Year | 2007 | 1997 |
Fundamental Metrics
Financial Performance| Metric | TDC | SRPT |
|---|---|---|
| Price | $29.80 | $21.28 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 8 | 29 |
| Target Price | ★ $30.13 | $26.23 |
| AVG Volume (30 Days) | 1.3M | ★ 2.9M |
| Earning Date | 02-10-2026 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 44.18 | N/A |
| EPS | ★ 1.21 | N/A |
| Revenue | $1,651,000,000.00 | ★ $2,413,715,000.00 |
| Revenue This Year | N/A | $13.72 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $25.18 | ★ N/A |
| Revenue Growth | N/A | ★ 47.15 |
| 52 Week Low | $18.43 | $10.42 |
| 52 Week High | $33.03 | $129.84 |
Technical Indicators
Market Signals| Indicator | TDC | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 51.53 | 50.54 |
| Support Level | $30.41 | $21.36 |
| Resistance Level | $31.16 | $22.52 |
| Average True Range (ATR) | 0.69 | 0.95 |
| MACD | -0.27 | -0.08 |
| Stochastic Oscillator | 22.16 | 40.66 |
Price Performance
Historical ComparisonAbout TDC Teradata Corporation
Teradata Corp focused on helping organizations improve business performance, enrich customer experiences, and integrate data across the enterprise. The company's platform provides companies with Harmonized Data: Trusted AI: Teradata VantageCloud: Teradata VantageCore: ClearScape Analytics: and Query Grid. The company generates majority of revenue from the United States.
About SRPT Sarepta Therapeutics Inc. (DE)
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Majority of company's product candidates are at an early stage of development.